Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo

Inflammation Research

Volumn 64, Issue 1, 2015, Pages 41-51

  Tanimoto, Atsuo ^a   Ogawa, Yoshihiro ^a   Oki, Chika ^a   Kimoto, Yukari ^a   Nozawa, Keisuke ^a   Amano, Wataru ^a   Noji, Satoru ^a   Shiozaki, Makoto ^a   Matsuo, Akira ^a   Shinozaki, Yuichi ^a   Matsushita, Mutsuyoshi ^a  

^a JAPAN TOBACCO INC   (Japan)

Author keywords

Collagen induced arthritis; Cytokine signaling; Janus kinase; JTE 052

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA INTERFERON; COLLAGEN; CYTOKINE; FOCAL ADHESION KINASE 1; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 6; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE INHIBITOR; JTE 052; METHOTREXATE; RECOMBINANT ENZYME; TOFACITINIB; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY CELL; JOINT DESTRUCTION; MAST CELL; MONOCYTE; MOUSE; NONHUMAN; RAT; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, EXPERIMENTAL; CELL CULTURE; CHEMICALLY INDUCED; DBA MOUSE; DISEASE MODEL; DRUG EFFECTS; LEWIS RAT; METABOLISM; PATHOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; B-LYMPHOCYTES; CELLS, CULTURED; COLLAGEN; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; IN VITRO TECHNIQUES; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-2; JANUS KINASES; MAST CELLS; METHOTREXATE; MICE; MICE, INBRED DBA; PROTEIN KINASE INHIBITORS; RATS; RATS, INBRED LEW; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84925534067     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-014-0782-9     Document Type: Article

References (21)

1. Boulay JL, O’Shea JJ, Paul WE. Molecular phylogeny within type I cytokines and their cognate receptors. Immunity. 2003;19:159–63.
2. Yamaoka K, Saharinen P, Pesu M, Holt VE 3rd, Silvennoinen O, O’Shea JJ. The Janus kinases (Jaks). Genome Biol. 2004;5:253.
3. O’Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity. 2012;36:542–50.
4. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26:127–32.
5. Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH, Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken). 2011;63:1150–8.
6. Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 2012;64:617–29.
7. Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, Study A3921063 Investigators, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367:616–24.
8. Boy MG, Wang C, Wilkinson BE, Chow VF, Clucas AT, Krueger JG, et al. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J Invest Dermatol. 2009;129:2299–302.
9. Vincenti F, Tedesco Silva H, Busque S, O’Connell P, Friedewald J, Cibrik D, et al. Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am J Transplant. 2012;12:2446–56.
10. Meyer DM, Jesson MI, Li X, Elrick MM, Funckes-Shippy CL, Warner JD, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond). 2010;7:41.
11. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003;302:875–8.
12. + T cells. Arthritis Rheum. 2012;64:1790–8.
13. Cohen S, Radominski SC, Gomez-Reino JJ, Wang L, Krishnaswami S, Wood SP, et al. Analysis of infections and all-cause mortality in Phase II, III and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheum. 2014.
14. Dinh M, Grunberger D, Ho H, Tsing SY, Shaw D, Lee S, et al. Activation mechanism and steady state kinetics of Bruton’s tyrosine kinase. J Biol Chem. 2007;282:8768–76.
15. Sasakawa T, Sasakawa Y, Ohkubo Y, Mutoh S. FK506 ameliorates spontaneous locomotor activity in collagen-induced arthritis: implication of distinct effect from suppression of inflammation. Int Immunopharmacol. 2005;5:503–10.
16. Konforte D, Simard N, Paige CJ. IL-21: an executor of B cell fate. J Immunol. 2009;182:1781–7.
17. Cornish AL, Campbell IK, McKenzie BS, Chatfield S, Wicks IP. G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol. 2009;5:554–9.
18. Toru H, Pawankar R, Ra C, Yata J, Nakahata T. Human mast cells produce IL-13 by high-affinity IgE receptor cross-linking: enhanced IL-13 production by IL-4-primed human mast cells. J Allergy Clin Immunol. 1998;102:491–502.
19. Swinney DC. Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001–2004: mechanisms leading to optimal efficacy and safety. Curr Top Med Chem. 2006;6:461–78.
20. Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115:3109–17.
21. + T cells. Clin Exp Immunol. 2007;148:288–95.